Clinical Ink Adds Sleep and Actigraphy Monitoring to Digital Health Platform
Life science technology firm Clinical Ink has expanded its digital health offerings by integrating five new connected devices for sleep and actigraphy monitoring into its eClinical platform.
Clinical Ink, a global life science technology company, has expanded its portfolio of digital health technologies. The company has added five new connected devices to its validated eClinical platform, which already integrates electronic clinical outcome assessments (eCOA) and glucose monitoring. These new additions provide capabilities for sleep staging, home sleep apnea testing, and research-grade actigraphy.
The expansion aims to address the growing need for accurate, real-world data collection from patient homes during clinical trials. By incorporating sleep and activity monitoring, Clinical Ink can provide researchers with continuous, objective data that may offer deeper insights into patient conditions and treatment efficacy. Actigraphy, in particular, allows for long-term tracking of sleep-wake patterns and activity levels.
Previously focused on eCOA solutions that digitize patient-reported outcomes and other clinical data, Clinical Ink's move to integrate biosensor data signifies a strategic shift towards a more comprehensive digital health data ecosystem. This integration is designed to streamline data capture, reduce manual entry errors, and potentially accelerate the clinical trial process.
The company stated that the enhanced platform intends to improve the efficiency of clinical research and the overall patient experience. This latest development supports Clinical Ink's broader strategy to deliver integrated digital solutions for the life sciences industry.